Supplementary Figure 2 from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

Dina Stroopinsky(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Keisuke Ito(Albert Einstein College of Medicine), Turner Kufe(Beth Israel Deaconess Medical Center), Hasan Rajabi(Harvard University), Ilene Galinsky(Dana-Farber Cancer Institute), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Caterina Nardella(Beth Israel Deaconess Medical Center), Yin Li(Ningbo University), Heidi Mills(Beth Israel Deaconess Medical Center), Pier Paolo Pandolfi(University of Turin), James D. Levine(Beth Israel Deaconess Medical Center), Yoram Reiter(Technion – Israel Institute of Technology)
Unknown
March 30, 2023
10.1158/0008-5472.22396167
Cited by 0

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k